MX2010002242A - Estimulación de ruta wnt en reprogramacion de celulas somaticas. - Google Patents

Estimulación de ruta wnt en reprogramacion de celulas somaticas.

Info

Publication number
MX2010002242A
MX2010002242A MX2010002242A MX2010002242A MX2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A MX 2010002242 A MX2010002242 A MX 2010002242A
Authority
MX
Mexico
Prior art keywords
somatic cells
methods
reprogramming
wnt pathway
compositions
Prior art date
Application number
MX2010002242A
Other languages
English (en)
Inventor
Rudolf Jaenisch
Ruth Foreman
Brett Chevalier
Alexander Marson
Richard A Young
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Publication of MX2010002242A publication Critical patent/MX2010002242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/45—Artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)

Abstract

La invención proporciona composiciones y métodos de uso en la reprogramación de células somáticas. Las composiciones y métodos de la invención son de uso, por ejemplo para generar o modular (por ejemplo, para mejorar) la generación de células madre pluripotentes inducidas al reprogramar células somáticas. Las células somáticas reprogramadas son útiles para varios propósitos, que incluyen tratar o prevenir una afección médica en un individuo. La invención proporciona además métodos para identificar un agente que reprograma células somáticas a un estado pluripotente y/o mejora la velocidad y/o eficiencia de la reprogramación. Ciertas composiciones y métodos se refieren a modular la ruta de Wnt.
MX2010002242A 2007-08-31 2008-08-29 Estimulación de ruta wnt en reprogramacion de celulas somaticas. MX2010002242A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96702807P 2007-08-31 2007-08-31
US18819008P 2008-08-06 2008-08-06
PCT/US2008/010249 WO2009032194A1 (en) 2007-08-31 2008-08-29 Wnt pathway stimulation in reprogramming somatic cells

Publications (1)

Publication Number Publication Date
MX2010002242A true MX2010002242A (es) 2010-06-01

Family

ID=40429192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002242A MX2010002242A (es) 2007-08-31 2008-08-29 Estimulación de ruta wnt en reprogramacion de celulas somaticas.

Country Status (10)

Country Link
US (6) US9102919B2 (es)
EP (2) EP3078738B1 (es)
JP (7) JP6151879B2 (es)
CN (1) CN101855338B (es)
AU (5) AU2008297011B2 (es)
CA (2) CA3006367A1 (es)
ES (2) ES2799897T3 (es)
MX (1) MX2010002242A (es)
RU (1) RU2492232C2 (es)
WO (1) WO2009032194A1 (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682828B2 (en) * 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
PT1970446E (pt) 2005-12-13 2011-09-01 Univ Kyoto Factor de reprogramação nuclear
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
SG193653A1 (en) 2007-03-23 2013-10-30 Wisconsin Alumni Res Found Somatic cell reprogramming
EP2145000A4 (en) 2007-04-07 2010-05-05 Whitehead Biomedical Inst REPROGRAMMING SOMATIC CELLS
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CN101855338B (zh) * 2007-08-31 2013-07-17 怀特黑德生物医学研究所 在程序重排体细胞中的wnt途径刺激
EP2090649A1 (en) * 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
WO2009102983A2 (en) * 2008-02-15 2009-08-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
SG10201607710UA (en) 2008-03-17 2016-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
KR101661940B1 (ko) 2008-05-02 2016-10-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵 초기화 방법
ES2587395T3 (es) * 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
CN105671065A (zh) 2008-06-13 2016-06-15 怀特黑德生物医学研究所 细胞编程和重编程
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
US9045737B2 (en) * 2008-12-13 2015-06-02 Dnamicroarray, Inc. Artificial three-dimensional microenvironment niche culture
KR101909847B1 (ko) 2008-12-17 2018-12-18 더 스크립스 리서치 인스티튜트 줄기 세포의 생성 및 유지
CN102575251B (zh) * 2009-05-18 2018-12-04 库尔纳公司 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
CN102459575A (zh) 2009-06-05 2012-05-16 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
JP2011004674A (ja) * 2009-06-26 2011-01-13 Fujitsu Ltd 誘導多能性幹細胞（ｉＰＳ細胞）の製造方法
JP6091893B2 (ja) 2009-07-08 2017-03-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 機能的に分化した体細胞の増強された自己再生を誘導するための方法
AU2010271249B2 (en) 2009-07-09 2016-01-28 Whitehead Institute For Biomedical Research Compositions and methods for mammalian genetics and uses thereof
US8709805B2 (en) * 2009-08-07 2014-04-29 Kyoto University Canine iPS cells and method of producing same
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
KR101874463B1 (ko) 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
US9453205B2 (en) 2009-10-31 2016-09-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
EP2496689B1 (en) * 2009-11-04 2015-05-20 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
JP2013510563A (ja) * 2009-11-13 2013-03-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 操作された微小胞を用いた真核細胞のリプログラミング
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
JPWO2011158852A1 (ja) * 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
KR20140063501A (ko) 2010-12-22 2014-05-27 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
JP2014501114A (ja) * 2010-12-31 2014-01-20 ウニヴェルズィテート・フューア・ボーデンクルトゥーア・ウィーン 人工多能性幹細胞および分化した細胞を生成する方法
KR101791926B1 (ko) 2011-07-25 2017-11-20 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도 만능 줄기 세포 스크리닝 방법
JP6208667B2 (ja) * 2011-10-03 2017-10-04 ユニベルシテ リブレ デ ブリュッセル 持続的ｈｉｖ感染症を処置するためのｈｉｖ−１遺伝子発現の再活性化
US20140248698A1 (en) 2011-10-21 2014-09-04 Arkray, Inc. Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow
EP2784153B1 (en) 2011-11-25 2018-01-03 Kyoto University Method for culturing pluripotent stem cell
RU2477314C1 (ru) * 2011-12-07 2013-03-10 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт патологии кровообращения имени академика Е.Н. Мешалкина" Минздравсоцразвития РФ, (ФГБУ "ННИИПК им. акад. Е.Н. Мешалкина" Минздравсоцразвития России) РЕКОМБИНАНТНАЯ ПЛАЗМИДА pSM-ZsGreen, КОДИРУЮЩАЯ БЕЛКИ SOX2 И С-MYC ЧЕЛОВЕКА И ФЛУОРЕСЦЕНТНЫЙ БЕЛОК ZsGreen, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ПОЛУЧЕНИЯ ИНДУЦИРОВАННЫХ ПЛЮРИПОТЕНТНЫХ СТВОЛОВЫХ КЛЕТОК ЧЕЛОВЕКА
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
US10077429B2 (en) 2012-10-23 2018-09-18 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP2955223B1 (en) 2013-02-08 2019-12-18 Kyoto University Production methods for megakaryocytes and platelets
US9738861B2 (en) 2013-03-06 2017-08-22 Kyoto University Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
WO2014145975A2 (en) 2013-03-15 2014-09-18 Whitehead Institute For Biomedical Research Cellular discovery platform for neurodegenerative diseases
WO2014148646A1 (ja) 2013-03-21 2014-09-25 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
KR102164270B1 (ko) 2013-03-25 2020-10-12 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 세포의 선별 방법
US10961508B2 (en) 2013-04-12 2021-03-30 Kyoto University Method for inducing alveolar epithelial progenitor cells
WO2014185358A1 (ja) 2013-05-14 2014-11-20 国立大学法人京都大学 効率的な心筋細胞の誘導方法
KR101870174B1 (ko) 2013-05-31 2018-06-22 아이하트 재팬 가부시키가이샤 하이드로겔을 포함하는 적층화된 세포 시트
BR112015030918A2 (pt) 2013-06-11 2017-12-05 Astellas Pharma Inc método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais
JP6378183B2 (ja) 2013-08-07 2018-08-22 国立大学法人京都大学 膵ホルモン産生細胞の製造法
CN105849255A (zh) 2013-09-05 2016-08-10 国立大学法人京都大学 新的产多巴胺神经前体细胞诱导方法
US10100283B2 (en) 2013-11-01 2018-10-16 Kyoto University Efficient chondrocyte induction method
EP3604499A1 (en) 2014-03-04 2020-02-05 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
WO2015140257A1 (en) 2014-03-19 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for inducing human cholangiocyte differentiation
JP7012432B2 (ja) 2014-07-14 2022-01-28 中外製薬株式会社 タンパク質のエピトープを同定するための方法
JP6824158B2 (ja) 2014-09-12 2021-02-03 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ アポリポタンパク質ｅを発現する細胞及びその使用
WO2016104717A1 (ja) 2014-12-26 2016-06-30 国立大学法人京都大学 肝細胞誘導方法
EP3770252A1 (en) 2015-01-26 2021-01-27 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP3259348A4 (en) 2015-02-17 2018-07-18 University Health Network Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes
JP2016202172A (ja) 2015-04-16 2016-12-08 国立大学法人京都大学 疑似膵島の製造方法
RU2621547C2 (ru) * 2015-06-26 2017-06-06 Андрей Степанович БРЮХОВЕЦКИЙ Способ дистанционной мультиволновой электромагнитной радионейроинженерии головного мозга человека
AU2016296741A1 (en) 2015-07-21 2018-02-22 The Children's Medical Center Corporation PD-L1 expressing hematopoietic stem cells and uses
SG10202111851YA (en) 2015-10-16 2021-12-30 Fate Therapeutics Inc Platform for the Induction & Maintenance of Ground State Pluripotency
WO2017179720A1 (ja) 2016-04-15 2017-10-19 国立大学法人京都大学 Ｃｄ８陽性ｔ細胞を誘導する方法
SG11201809279YA (en) 2016-04-22 2018-11-29 Univ Kyoto Method for producing dopamine-producing neural precursor cells
WO2017196175A1 (en) 2016-05-12 2017-11-16 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium.
CA3038721A1 (en) * 2016-09-30 2018-04-05 Mayo Foundation For Medical Education And Research Viral vectors for nuclear reprogramming
US20200141921A1 (en) 2016-12-27 2020-05-07 Sumitomo Chemical Company, Limited Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells
WO2018135646A1 (ja) 2017-01-20 2018-07-26 国立大学法人京都大学 ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法
WO2018139548A1 (ja) 2017-01-26 2018-08-02 国立大学法人大阪大学 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法
JP7171055B2 (ja) 2017-03-14 2022-11-15 国立大学法人京都大学 多能性幹細胞からヘルパーｔ細胞を製造する方法
KR20230150412A (ko) 2017-05-25 2023-10-30 고쿠리츠 다이가쿠 호진 교토 다이가쿠 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법
JP6758631B2 (ja) 2017-06-19 2020-09-23 国立大学法人大阪大学 角膜内皮細胞マーカー及びその利用
WO2018235583A1 (ja) 2017-06-19 2018-12-27 公益財団法人神戸医療産業都市推進機構 多能性幹細胞の分化能の予測方法及びそのための試薬
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
WO2019078263A1 (ja) 2017-10-17 2019-04-25 国立大学法人京都大学 多能性幹細胞から人工神経筋接合部を得る方法
SG11202100260QA (en) 2018-07-13 2021-02-25 Univ Kyoto METHOD FOR PRODUCING γδ T CELLS
JP7285015B2 (ja) 2018-07-19 2023-06-01 国立大学法人京都大学 多能性幹細胞由来の板状軟骨およびその製造方法
US20210332329A1 (en) 2018-07-23 2021-10-28 Kyoto University Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
EP3892722A4 (en) 2018-12-06 2022-10-05 Kirin Holdings Kabushiki Kaisha METHOD FOR PRODUCING T LYMPHOCYTES OR NK CELLS, MEDIUM FOR CULTIVATING T LYMPHOCYTES OR NK CELLS, METHOD FOR CULTURING T LYMPHOCYTES OR NK CELLS, METHOD FOR MAINTAINING THE UNDIFFERENTIATED STATE OF UNDIFFERENTIATED T LYMPHOCYTES, AND GROWTH ACCELERATION FOR T LYMPHOCYTES OR NK CELLS
EP3900787A4 (en) 2018-12-21 2022-02-23 Kyoto University CARTILAGE-LIKE TISSUE WITH LOCALIZED LUBRICINE, METHOD FOR THE PRODUCTION THEREOF, AND COMPOSITION COMPRISING IT FOR THE TREATMENT OF ARTICULAR CARTILAGE LESIONS
WO2020138371A1 (ja) 2018-12-26 2020-07-02 キリンホールディングス株式会社 改変ｔｃｒ及びその製造方法
CA3141455A1 (en) 2019-05-20 2020-11-26 Ajinomoto Co., Inc. Expansion culture method for cartilage or bone precursor cells
EP4074321A4 (en) 2019-12-12 2024-01-03 Univ Chiba Nat Univ Corp FREEZE DRIED PREPARATION CONTAINING MEGAKARYOCYTES AND PLATELETS
WO2021174004A1 (en) 2020-02-28 2021-09-02 Millennium Pharmaceuticals, Inc. Method for producing natural killer cells from pluripotent stem cells
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
EP4170020A1 (en) 2020-06-17 2023-04-26 Kyoto University Chimeric antigen receptor-expressing immunocompetent cells
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
WO2022019152A1 (ja) 2020-07-20 2022-01-27 学校法人 愛知医科大学 多能性細胞の未分化維持培養用組成物、多能性細胞の未分化維持培養用培地、多能性細胞の未分化状態での維持培養方法、および多能性細胞の製造方法
EP4202041A1 (en) 2020-08-18 2023-06-28 Kyoto University Method for maintaining and amplifying human primordial germ cells / human primordial germ cell-like cells
EP4310176A1 (en) 2021-03-17 2024-01-24 Astellas Pharma Inc. Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein
CN117597433A (zh) 2021-04-30 2024-02-23 国立研究开发法人理化学研究所 视网膜色素上皮细胞的条状聚集体、用于制造其的装置和制造方法、以及含有该条状聚集体的治疗药物
CN117413051A (zh) 2021-06-04 2024-01-16 麒麟控股株式会社 细胞组合物、细胞组合物的制造方法和含有细胞组合物的药物组合物
EP4353243A1 (en) 2021-06-10 2024-04-17 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
BR112023026141A2 (pt) 2021-06-15 2024-03-05 Takeda Pharmaceuticals Co Métodos para produzir uma população de células enriquecida em células nk, para produzir células nk derivadas de células-tronco pluripotentes induzidas, para tratar um sujeito em necessidade de terapia de células e para produzir uma população de células compreendendo células progenitoras hematopoiéticas cd34+, e, populações de células nk e de células não classificadas
WO2023286832A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞の製造方法
EP4372080A1 (en) 2021-07-15 2024-05-22 Astellas Pharma Inc. Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level
WO2023017848A1 (ja) 2021-08-11 2023-02-16 国立大学法人京都大学 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法
WO2023085356A1 (ja) 2021-11-11 2023-05-19 株式会社ヘリオス 遺伝子改変多能性幹細胞、それ由来の免疫担当細胞、それらの製造方法及びそれらの用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
US20010012513A1 (en) 1996-08-19 2001-08-09 University Of Massachusetts Embryonic or stem-like cell lines produced by cross species nuclear transplantation
KR20010090008A (ko) 1998-11-11 2001-10-17 추후제출 동종이계 조혈 세포 이식을 개선시키는 방법 및 조성물
IL129966A (en) 1999-05-14 2009-12-24 Technion Res & Dev Foundation ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
US6608063B2 (en) 1999-12-17 2003-08-19 Chiron Corporation Pyrazine based inhibitors of glycogen synthase kinase 3
FR2804959B1 (fr) 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
US20040087016A1 (en) 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
AU2002305205A1 (en) 2001-04-20 2002-11-05 Jingrong Cao 9-deazaguanine derivatives as inhibitors of gsk-3
JP2005500101A (ja) * 2001-07-16 2005-01-06 エドワーズ　ライフサイエンシーズ　コーポレイション 組織工学心臓弁
US6916798B2 (en) 2001-08-03 2005-07-12 Vertex Pharmaceuticals Incorporated Inhibitors of GSK-3 and uses thereof
WO2003049739A1 (en) 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
JP4741189B2 (ja) * 2002-02-08 2011-08-03 ユニヴァーシティ オブ サウス フロリダ 増殖した細胞系およびその使用方法
US6835810B2 (en) 2002-05-13 2004-12-28 Geneshuttle Biopharma, Inc. Fusion protein for use as vector
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7153832B2 (en) 2003-04-07 2006-12-26 The Board Of Trustees Of The Leland Stanford Junior University Compositions of active Wnt protein
CA2528805A1 (en) 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
WO2005080598A1 (ja) * 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
DE602006009965D1 (de) 2005-11-28 2009-12-03 Choongwae Pharma Corp Serumfreie expansion von zellen in kultur
PT1970446E (pt) * 2005-12-13 2011-09-01 Univ Kyoto Factor de reprogramação nuclear
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2457995A1 (en) 2006-03-30 2012-05-30 The University Court of The University of Edinburgh Culture medium containing kinase inhibitors, and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP2145000A4 (en) 2007-04-07 2010-05-05 Whitehead Biomedical Inst REPROGRAMMING SOMATIC CELLS
CN101855338B (zh) * 2007-08-31 2013-07-17 怀特黑德生物医学研究所 在程序重排体细胞中的wnt途径刺激
US20100330677A1 (en) 2008-02-11 2010-12-30 Cambridge Enterprise Limited Improved Reprogramming of Mammalian Cells, and Cells Obtained
CN105671065A (zh) 2008-06-13 2016-06-15 怀特黑德生物医学研究所 细胞编程和重编程
US20120034192A1 (en) 2008-09-19 2012-02-09 Young Richard A Compositions and methods for enhancing cell reprogramming
EP2421956A4 (en) 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS

Also Published As

Publication number Publication date
AU2008297011B2 (en) 2014-06-12
US9593311B2 (en) 2017-03-14
EP3078738A1 (en) 2016-10-12
USRE49281E1 (en) 2022-11-08
US9102919B2 (en) 2015-08-11
CA3006367A1 (en) 2009-03-12
US20170218341A1 (en) 2017-08-03
AU2017239605A1 (en) 2017-10-26
AU2014224119B2 (en) 2017-08-03
JP6470233B2 (ja) 2019-02-13
AU2014224119A1 (en) 2014-10-02
JP2022087313A (ja) 2022-06-09
US20100310525A1 (en) 2010-12-09
RU2010112393A (ru) 2011-10-10
WO2009032194A1 (en) 2009-03-12
CN101855338B (zh) 2013-07-17
AU2008297011A1 (en) 2009-03-12
EP2198011B1 (en) 2016-06-08
AU2022291621A1 (en) 2023-02-02
JP7377309B2 (ja) 2023-11-09
AU2020200825B2 (en) 2022-09-29
AU2017239605B2 (en) 2019-11-07
EP3078738B1 (en) 2020-05-20
JP2019115358A (ja) 2019-07-18
JP2014087373A (ja) 2014-05-15
JP6151879B2 (ja) 2017-06-21
US20160068819A1 (en) 2016-03-10
RU2492232C2 (ru) 2013-09-10
US20230279359A1 (en) 2023-09-07
CN101855338A (zh) 2010-10-06
JP2010537634A (ja) 2010-12-09
JP2016171818A (ja) 2016-09-29
EP2198011A4 (en) 2010-09-08
JP2022087314A (ja) 2022-06-09
ES2589122T3 (es) 2016-11-10
ES2799897T3 (es) 2020-12-22
AU2020200825A1 (en) 2020-02-20
EP2198011A1 (en) 2010-06-23
CA2698091A1 (en) 2009-03-12
JP2017140054A (ja) 2017-08-17
CA2698091C (en) 2018-07-03
US20190284537A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
EP2198011A4 (en) STIMULATION OF THE WNT PATHWAY IN THE REPROGRAMMING OF SOMATIC CELLS
WO2010033920A3 (en) Compositions and methods for enhancing cell reprogramming
MY159971A (en) Multipotent/pluripotent cells and methods
PH12015500694A1 (en) Compositions and methods for enhancing plant growth
MX2015016399A (es) Composiciones y metodos para mejorar la germinacion.
TR200906329T1 (tr) Kanser Hastalarında Kemik Gelişimini Desteklemek için A
WO2011082038A3 (en) Improved reprogramming compositions
GB2497240A (en) Soil treatment process
WO2010124142A3 (en) Cell compositions derived from dedifferentiated reprogrammed cells
CU20120078A7 (es) Composiciones para tratar náusea y vómito centralmente mediados
WO2011071476A3 (en) Compositions and methods for engineering cells
AR068194A1 (es) Composiciones y metodos de tratamiento de semillas
MY160595A (en) Energetic modulation of nerves
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
MX2012004881A (es) Metodos para reprogramar células y sus usos.
UA115534C2 (uk) Спосіб та композиція для боротьби з бур'янами (варіанти)
MY176922A (en) Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
WO2010083170A3 (en) Cell stimulation using quantum dots
PH12015500619A1 (en) Plant regulatory elements and uses thereof
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2009143421A3 (en) Methods for promoting fusion and reprogramming of somatic cells
AR061816A1 (es) Una nueva cepa de trichoderma atroviride, un medio de cultivo conteniendola, asi como la utilizacion de dicha cepa en particular como estimulante de la germinacion y/o del crecimiento de las plantas
WO2010022194A3 (en) Compositions and methods for generation of pluripotent stem cells
EA201590507A1 (ru) Композиции и способы, предусматривающие последовательности, определяющие мужскую фертильность

Legal Events

Date Code Title Description
FG Grant or registration